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Abstract
Diabetes type 2 mellitus (T2DM) is the most common extrahepatic association of hepa-
titis C virus (HCV) infection. Substantial research has suggested that insulin resistance 
(IR) has crucial importance in development of type 2 diabetes in HCV-infected patients. 
Several pathophysiological mechanisms are proposed, such as direct effect of HCV pro-
teins on inhibition of the insulin-signaling pathway inducing central insulin resistance 
(IR), while overproduction of inflammatory cytokines and increased lipolysis promote 
peripheral IR. IR in HCV-infected patients is associated with impaired sustained viro-
logic response (SVR) and higher incidence of hepatocellular carcinoma (HCC). Some, but 
not all, studies have shown improvements in achieving SVR in patients with interferon/
ribavirin (RBV) therapy co-treated with metformin or pioglitazone as well as beneficiary 
effect on the incidence of hepatocellular carcinoma. Recent studies indicate that response 
to the new direct-acting antiviral (DAA) treatments is unaffected by insulin resistance 
thus diminishing importance of IR in the new era of DAA. Additionally, viral eradication 
by DAAs has been shown to ameliorate insulin resistance, attenuating the risk of new-
onset diabetes type 2. However, those metabolic improvements are sustainable long after 
the treatment remains unclear.
Keywords: hepatitis C infection, diabetes type 2, insulin resistance, insulin signaling, antiviral 
agents, antidiabetic agents
1. Introduction
Diabetes is a group of metabolic diseases characterized by hyperglycemia, which in vast 
majority of cases fall into two broad etiopathogenetic categories: type 1 (T1DM) and type 
2 diabetes mellitus (T2DM) [1, 2]. Frequency of type 1 is relatively low in comparison with 
type 2, which accounts for over 90% of cases globally [3]. For development of type 2 diabetes 
mellitus, several pathophysiologic mechanisms are responsible such as insulin resistance 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
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(IR), impairment of insulin secretion, and increased hepatic glucose production [4]. Chronic 
and uncontrolled diabetes results in serious comorbidities such as retinopathy, neuropathy, 
nephropathy, and cardiovascular diseases a leading cause of mortality [5].
So far, numerous studies indicate that diabetes mellitus could be the most common extra-
hepatic manifestation of chronic hepatitis C virus (HCV) [6]. A meta-analysis of 34 studies 
confirmed a positive correlation between HCV infection and increased prevalence of diabetes 
mellitus type 2 in comparison with general population [7]. Additionally, many epidemiologi-
cal studies indicate that HCV-infected patients have higher prevalence of diabetes in compari-
son with hepatitis B virus (HBV)-infected patients [8].
2. Diabetes type 2 and chronic hepatitis C infection
Although HCV infection is primarily affecting liver, there are other well-known extrahepatic 
manifestations of chronic hepatitis C [9, 10]. Mechanisms of those disorders are related to 
extrahepatic tropism of the HCV or by immunological process in which chronic infection 
leads to the development of autoimmune-mediated disease [11].
Since the discovery of HCV in 1989, great attention is paid to the development of type 2 
diabetes mellitus during chronic hepatitis C virus infection [12]. Already in 1994, Allison 
et al. showed that 50% of HCV-related cirrhosis have diabetes mellitus compared to 9% 
with cirrhosis related to other causes [13]. For a long time, a loss of liver endocrine func-
tion due to progression of fibrosis in chronic hepatitis was considered to be responsible for 
the development of insulin resistance [14]. To examine the effect of HCV infection with-
out concomitant cirrhosis on development of diabetes mellitus, Knobler et al. performed 
an oral glucose tolerance test in patients with chronic hepatitis B and C without cirrhosis 
[15]. Study showed that 33% of HCV patients had type 2 diabetes, whereas only 12% of 
patients with chronic hepatitis B (HBV) infection and 6% of healthy volunteers had glucose 
metabolism impairment, indicating that diabetes occurs in the early stages of the HCV-
induced liver disease. Also, liver biopsies from HCV-infected patients with diabetes had 
significantly higher fibrosis grade, inflammatory activity, and steatosis compared to HCV 
patients without diabetes.
The correlation between genotype of HCV and the level of insulin resistance has also been 
recognized. In a study of Hui, significantly lower insulin resistance index (HOMA-IR) was 
registered in patients with genotype 3 HCV in comparison with other genotypes [16]. Another 
study showed significantly higher median HOMA-IR in patients with hepatic steatosis 
infected with genotype 1 HCV than in patients with genotype 3 [17]. On the other hand, 
patients with genotype 3 had a higher probability of having moderate-to-severe steatosis, 
compared to those with non-3 genotypes [18]. Moreover, in type 1 genotype fatty liver disease 
occurred if there are other risk factors present at time like diabetes, adiposity, and insulin 
resistance implicating specific viral sequences responsible for fat accumulation independently 
of other risk factors. To clarify, there are two distinct disorders, viral, and metabolic steatosis 
[19]. This is important since whatever the mechanism, viral steatosis does not seem to impact 
liver fibrosis progression rate, although HCV genotype 3 is independently associated with 
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increased fibrosis progression. Also, viral steatosis does not impair response to interferon-a 
(IFN-a). Alternatively, steatosis due to the metabolic syndrome and IR is associated with both 
accelerated fibrosis progression and poor response to IFN-a-based therapy.
2.1. Hepatitis C–induced insulin resistance
Substantial research has suggested that insulin resistance has crucial importance in develop-
ment of type 2 diabetes in HCV-infected patients [17]. A study of Hui et al. showed higher 
levels of insulin, C peptide, and HOMA-IR in 121 hepatitis C virus patients with stage 0 or 1 
hepatic fibrosis compared with healthy controls proposing that HCV may induce IR irrespec-
tive to stage of liver fibrosis [16], although higher levels of liver fibrosis were associated with 
increased stage of insulin resistance. These findings were confirmed with other studies, and 
dependence of insulin resistance is determined with severity of liver fibrosis [6].
HCV-infected patients also develop insulin resistance in hepatic and peripheral tissues while 
pathogenetic mechanism is not clear [20]. Although HCV is hepatotropic virus, its genome 
has been detected in numerous extrahepatic tissues including pancreatic acinar cells and epi-
thelial cells of pancreatic duct [21, 22]. Several studies demonstrated direct effect of the HCV 
proteins on inhibition of the insulin-signaling pathway. Key mediators of insulin-signaling 
cascade are insulin receptor substrate (IRS) 1 and 2. Disruption of IRS1 results in insulin resis-
tance, while for development of diabetes mellitus, disruption of IRS2 is needed [23, 24]. In 
HCV, core-transgenic mice as well core-transfected human hepatoma cells downregulation 
of IRS1 and IRS2 were observed [25]. A proposed mechanism was that HCV core protein 
induced upregulation of suppressor of cytokine signaling (SOCS) 3 resulting in proteasomal 
degradation of IRS1 and IRS2 through ubiquitination. Furthermore, Alberstein et al. reported 
several impairments in the insulin-signaling cascade linked to a proteasome degradation of 
IRS1 protein in cell lines transfected with HCV core protein [26]. HCV infection increased glu-
coneogenesis by promoting the expression of gluconeogenic genes, such as glucose 6 phos-
phatase (G6P) and phosphoenolpyruvate carboxyl kinase 2 (PCK2), which had adverse effect 
on insulin resistance [19]. On the other hand, HCV downregulated the expression of glucose 
transporter GLUT 4, which resulted in decreased glucose uptake and increased level of glu-
cose in plasma leading to impairment of glucose metabolism [27].
Also, HCV core protein of genotype 3 downregulated peroxisome proliferator activating 
receptor (PPARγ) and upregulated SOCS 7 [28]. Beside its effect on insulin-signaling cas-
cade, it is suggested that HCV has the ability to cause dysfunctions of cell organelles such 
as mitochondria and endoplasmatic reticulum which leads to further impairment of insulin-
signaling pathway [29].
In studies where euglycemic insulin clamp was used, insulin resistance was determined 
mainly in peripheral tissues such as skeletal muscle rather than in liver [30]. Clearly, the effect 
of cytokines was necessary for the development of peripheral insulin resistance due to the 
tropism of HCV for hepatic tissue. Several studies emphasized the role of the overproduced 
tumor necrosis factor alpha (TNF-α) in HCV-induced insulin resistance [31–33]. Inhibitory 
role of TNF-α is achieved through activation of serine/threonine kinases, which resulted in 
uncoupling of insulin receptor substrate protein from downstream effectors [34]. Furthermore, 
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the importance of the TNF-α in HCV-induced IR was confirmed by the study of Shintani et al., 
which used transgenic mice with characteristic expression of HCV core protein in the liver. 
Insulin resistance and impaired glucose metabolism were observed in this transgenic model, 
while administration of an antitumor necrosis factor-alpha antibody restored insulin sensi-
tivity [35]. TNFα-induced insulin resistance was also achieved through indirect mechanisms 
such as increased lipolysis resulting in regulation of expression of several adipocyte genes 
that modulate insulin sensitivity [36]. Dysfunction of lipid metabolism triggers lipotoxicity 
through increased production of free fatty acids, which promotes insulin resistance [37]. Along 
TNF-α, it is proposed that some other cytokines such as IL-6 and numerous adipokines have a 
role in pathogenesis of HCV-induced IR as well in steatosis of nonalcoholic fatty liver disease 
[38, 39]. Possible pathophysiological mechanisms of HCV-induced IR are shown in Figure 1.
3. Treatment of insulin resistance and diabetes with the eradication of 
viral infection
If HCV is one of the causal factors of insulin resistance, then clearance of viremia might be a 
way to reduce IR [40]. Additionally, viral eradication has been shown to ameliorate insulin 
resistance, attenuating the risk of new-onset T2DM [41].
Figure 1. Proposed mechanisms involved in pathogenesis of HCV-induced insulin resistance and diabetes type 2.
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Several observational studies indicated that eradication of HCV with interferon (IFN) and 
ribavirin (RBV) is associated with improved insulin sensitivity [42–44]. There are case reports 
that describe improvements in glycemic control with both IFN/RBV and IFN/RBV/telaprevir 
treatment. However, those improvements were observed only during the treatment phase, 
with the recurrence of diabetes when antiviral therapy ended [45, 46]. Case report by Doyle 
et al. was first to demonstrate complete remission of diabetes with viral clearance beyond the 
treatment phase, which may be due to the differences in antiviral treatment response [47]. In 
addition, several studies reported decreasing number of patients with IR treated with inter-
feron IFN/RBV therapies after achievement of sustained virologic response (SVR) [40, 48–50]. 
Viral clearance is the most possible mechanism through which antiviral therapy ameliorates 
IR rather than a direct pharmacological effect of IFN/RBV.
A few studies [42, 43, 50] reported reduced incidence of T2DM among patients who achieved 
SVR. Although T2DM occurrence is associated with a genetic predisposition, it is also influ-
enced by lifestyle-related aspects. For instance, one study showed that viral eradication 
induced a two-third reduction in the risk of T2DM incidence, but the authors did not report 
data regarding family history, smoking habit, and physical activity [42]. Reduced incidence 
of IR and T2DM in chronic hepatitis C (CHC) patients who achieved SVR after therapy, most 
likely depended on the genetic, demographic, clinical, histological, and lifestyle character-
istics of the patients. For this reason, counseling on diet and physical activity should not be 
excluded by the eradication of HCV in patients with predisposing factors for T2DM.
The clinical impact of successful antiviral therapy on the long-term outcome of T2DM in dia-
betics with CHC is still unknown, mainly because of the lack in proper prospective studies 
although data from population-based research in Taiwan reported improved renal and car-
diovascular outcomes in diabetic patients treated with antiviral HCV treatment [41].
High therapeutic efficacy of direct-acting antivirals (DAAs) will ensure viral eradication in 
a large number of diabetic cirrhotic patients, which will enable better understanding of the 
impact of the virus on T2DM outcome. One retrospective study reported a significant decrease 
in glycated hemoglobin (HbA1C) 6 months after HCV eradication with sofosbuvir, although 
the mechanism responsible for this improvement remains unknown [51]. In addition, other 
studies demonstrated the efficacy of DAAs (telaprevir and danoprevir) in improving IR and 
even restoring insulin sensitivity after achieving SVR, but only in genotype 1 patients [52, 53]. 
However, data for DAA effect on insulin resistance in other genotype HCV infected patients 
are lacking thus future studies are needed to conclude whether this effect is achievable in all 
genotypes.
4. Influence of insulin resistance and diabetes mellitus in treatment of 
hepatitis C infection
Since patients with chronic hepatitis C infection are twofold to threefold more likely to develop 
type 2 diabetes, which reduces their chances of achieving a sustained virologic response, the 
question is can we achieve better SVR by reducing insulin resistance. A  meta-analysis of 17 
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studies has shown that insulin sensitivity was associated with a higher rate of SVR in com-
parison with insulin resistance. Elevated HOMA-IR was associated with a lower cure rate 
of patients with hepatitis C treated with Peg-IFN-α/ribavirin irrespective of genotype, and 
the more difficult-to-treat cohort, the better the HOMA-IR prediction [54]. In addition, IR 
was associated with a higher incidence of hepatocellular carcinoma (HCC) in patients with 
hepatitis C virus [55], thus improving IR and correcting hyperinsulinemia may improve the 
prognosis of HCV cirrhosis.
Therapy for the T2DM in patients with liver diseases is generally the same as that without 
liver disease. Only patients with evidence of liver cirrhosis have altered drug metabolism, and 
there is no evidence that patients with liver disease are predisposed to hepatotoxicity [56].
4.1. Biguanides
Metformin is considered as the drug of choice in HCV patients with IR or T2DM since it 
generally does not cause hepatotoxicity [57], although there are sporadic case reports of met-
formin induced acute liver injury [58]. Some, but not all studies, have shown improvements 
in achieving SVR in patients with interferon/ribavirin therapy co-treated with metformin 
Study population/design Treatment Outcome Results








123 genotype 1 CHC with IR/
Prospective study
Metformin 
850 mg TID vs. 
placebo
SVR 53 vs. 42%, p = NS
Sharifi et al. [61] 140 CHC patients/Prospective study Metformin 
500 mg TID vs. 
Placebo
SVR 75 vs. 79%, p = NS
Nkontchou 
et al. [62]
100 diabetic patients with HCV 
cirrhosis/Prospective study
Metformin, 





9.5 vs. 31.2% 
(p = .001)
Lee et al. [63] 800,000 health insurance 
beneficiaries/Prospective study
Metformin vs. 









diabetic levels (HR, 
0.12), p = significant
Chen et al. [64] 53 diabetic and 82 nondiabetic 









1 year, 95 vs. 74.5%
5 years, 60.5 vs. 
26.2%
Donadon et al. 
[65]




and LC patients 
vs. SU and 
insulin
Risk of HCC >80% risk reduction, 
p = significant
Table 1. Summary of trials evaluating metformin use in patients with chronic HCV and T2DM or IR.
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[59–61] (Table 1). Increasing evidence points out that metformin is independently associ-
ated with reduced risk for HCC and liver-related death/transplantation [62–65] (Table 1). 
Metformin is frequently discontinued once cirrhosis is diagnosed because of concerns about 
an increased risk of adverse effects in patients with liver impairment. However, the study 
from Zhang et al. on 250 diabetic patients who developed cirrhosis showed that patients 
who continued metformin had a significantly longer median survival than those who dis-
continued metformin. In other words, metformin was found to be an independent predictor 
of better survival [66]. It is reasonable to conclude that metformin should remain a first-line 
option for patients with T2DM and chronic compensated HCV; however, more prospective, 
randomized controlled trials are needed to confirm safety and efficacy of metformin.
4.2. Thiazolidinediones
Thiazolidinediones (TZDs) are the only real insulin sensitizers available as they act pri-
marily through stimulation peroxisome proliferator-activated receptor PPAR-Y decreas-
ing insulin resistance in the liver and peripheral tissues. However, only few studies 
showed that pioglitazone improved virologic response to peginterferon alpha-2b/ribavi-
rin combination therapy in overweight hepatitis C genotype 4 patients, while there was 
no effect in other genotypes [67–70] (Table 2). Also, recent data suggested that piogli-
tazone could decrease a risk of HCC recurrence in the group of patients with a BMI ≥24 
[71] (Table 2).
TZD use is not recommended in advanced liver cirrhosis because of the reported cases 
of acute cholestatic hepatitis [72]. Current recommendation is that serum ALT levels are 
evaluated before the initiation of rosiglitazone and pioglitazone therapy and that therapy 
should not be initiated if there is evidence of active liver disease.




untreated patients with CHC 
and IR/Prospective study
Pioglitazone vs. no 
pioglitazone + standard 
care PegIFN/RBV






150 treatment-naive HCV 
genotype 1 patients/Prospective 
study
Pioglitazone vs. no 
pioglitazone + standard 
care PegIFN/RBV
SVR No significant 
difference between 
groups
Marks et al. 
[70]
19 previous non responders to 
PegIFN-RBV/Pilot study
Pioglitazone vs. no 
pioglitazone during 
24 week before PegIFN/
RBV/PIO
SVR 15% achieved 
SVR, no significant 
difference
Sumie et al. 
[71]
85 HCV-infected HCC patients/
Prospective study






in a group with 
BMI >24 kg/m2
Table 2. Summary of trials evaluating pioglitazone use in patients with chronic HCV and T2DM or IR.




Incretins are gut-derived hormones, mainly glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP), that are secreted at low basal levels in the fasting 
state. Circulating levels increase rapidly and transiently following food ingestion. GLP-1R 
agonists control blood glucose through regulation of islet function, principally through acti-
vation of insulin-secreting beta cell in pancreas, and inhibition of glucagon secretion. In short 
term, it enhances glucose-induced insulin secretion, but continuous GLP-1 receptor activation 
also increases insulin synthesis, and beta cell proliferation and neogenesis. Dipeptidyl pep-
tidase (DPP)-4 inactivates incretin hormones including GLP-1. Therefore, GLP-1 agonists as 
well as (DPP)-4 inhibitors are used as antidiabetic agents [73, 74].
Itou et al. found decreased serum GLP-1 levels and increased DPP-4 expression in the 
ileum, liver, and serum in HCV patients compared to control group and HBV group, thus 
concluding that altered expression of GLP-1 may play a role in the development of HCV-
associated glucose intolerance [75]. Recent studies on GLP-1 have shown slowing of the 
progression of non-acoholic fatty liver disease (NAFLD) by direct effects on lipid metabo-
lism in hepatocytes, and on inflammation in the liver [76]. A case–control study reported a 
reduction in HbA1C without side effects when treating HCV patients with DPP-4 inhibitors 
[77]. Nevertheless, further larger studies are needed to support the use of incretin mimetics 
in patients with advanced hepatic diseases.
4.3.1. Insulin
Insulin has been considered as the drug of choice in patients with diabetes and decompensated 
liver disease due to short half-life. However, one study in Japan found that exogenous insulin and 
a second-generation sulfonylurea were associated with a higher incidence of HCC in hepatitis 
C patients [78], whereas other studies showed reduced risk of HCC with the use of metformin, 
compared with SUs and insulin [79]. One meta-analysis of observational studies summarized the 
impact of antidiabetic medication on the risk of HCC: insulin and sulfonylurea (SU) increased 
the risk, metformin reduced it, and TDZs did not change it [80]. Insulin requirements may vary 
because patients with decompensated liver disease can have decreased requirements due to 
reduced capacity for gluconeogenesis or an increased need for insulin due to insulin resistance. 
Thus, there is need for careful glucose monitoring and frequent dose adjustments of insulin.
In conclusion, traditionally medications used to overcome IR are metformin and thiazolidin-
ediones, but their effect on SVR and incidence of HCC remains an open question. However, 
new promising agents such as GLP-1 receptor agonists could further improve outcome and 
prognosis of HCV-infected patients with metabolic disturbances.
5. Conclusion
Without a doubt, IR in HCV-infected patients is associated with impaired SVR and higher inci-
dence of hepatocellular carcinoma as well as higher incidence of diabetes type 2 accompanied 
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by other metabolic disturbances. Evidence of beneficiary effect of metformin or pioglitazone 
co-treatment in patients with interferon/ribavirin therapy on achieving SVR or incidence of 
HCC in HCV patients are scarce and ambiguous, leaving more room for questions than offer-
ing potential solutions. However, recently published research suggests that response to the 
new direct-acting antiviral treatments is not dependent on insulin resistance thus diminishing 
importance of IR in the new era of DAA. Furthermore, if we postulate that HCV induces insu-
lin resistance than achieving SVR could ameliorate it. Evidence supporting this hypothesis 
was recently published showing that insulin resistance disappeared after viral eradication 
by DAAs consequently decreasing a risk of diabetes type 2. In conclusion, further studies are 
needed to constitute how HCV induces insulin resistance, what effects different HCV thera-
pies have on improving glycemic outcomes, and whether those metabolic improvements are 
permanent and still present after the treatment.
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